Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE).
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE).
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016 Jan; 75(1):196-202.
View in:
PubMed
subject areas
Adult
Adult
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Biomarkers
Biomarkers
Double-Blind Method
Double-Blind Method
Drug Administration Schedule
Drug Administration Schedule
Drug Therapy, Combination
Drug Therapy, Combination
Female
Female
Glucocorticoids
Glucocorticoids
Humans
Humans
Immunologic Factors
Immunologic Factors
Injections, Intravenous
Injections, Intravenous
Injections, Subcutaneous
Injections, Subcutaneous
Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic
Male
Male
Middle Aged
Middle Aged
Severity of Illness Index
Severity of Illness Index
Treatment Outcome
Treatment Outcome
authors with profiles
Joan Merrill